What Is SS-31?
SS-31 peptide — also known as Elamipretide, MTP-131, or Bendavia — is a synthetic tetrapeptide designed specifically to target mitochondria. With the systematic name D-Arg-Dmt-Lys-Phe-NH2, it was developed by researchers at Cornell University and has progressed into clinical trials for cardiac and renal applications, making it one of the more clinically advanced research peptides with a strong preclinical foundation. SS-31 accumulates selectively in mitochondrial inner membranes, where it interacts with cardiolipin — a phospholipid critical for the structural integrity and functional efficiency of the electron transport chain.
The research interest in SS-31 has grown significantly as the role of mitochondrial dysfunction in ageing, heart failure, kidney disease, and neurodegenerative conditions has become better characterised. With 260 monthly searches in Australia, SS-31 occupies a niche but scientifically sophisticated position in the research peptide landscape.
Mechanism: Cardiolipin Interaction and Electron Transport Chain Efficiency
SS-31's primary mechanism involves its selective accumulation in mitochondrial inner membranes, driven by the alternating positively and negatively charged residues in its sequence. Once localised to the inner membrane, SS-31 interacts with cardiolipin — a unique four-tailed phospholipid found almost exclusively in mitochondrial inner membranes. Cardiolipin plays critical roles in organising the electron transport chain complexes into supercomplexes that optimise electron transfer efficiency and minimise reactive oxygen species (ROS) generation.
When cardiolipin is oxidised or its structure is disrupted (as occurs in ageing and disease), electron transport chain efficiency falls and ROS production increases. SS-31 appears to stabilise cardiolipin and restore more efficient electron flow, reducing ROS generation and improving ATP production per unit of oxygen consumed. This mitochondrial efficiency restoration is the central mechanism behind SS-31's observed effects across diverse research models.
Research Applications: Heart, Kidney, and Ageing
SS-31's research applications centre on tissues with high mitochondrial density and energy demands. Cardiac research has produced some of the most compelling data, with SS-31 demonstrating protective effects in models of myocardial ischaemia-reperfusion injury and heart failure. Clinical trials in heart failure patients (PROGRESS-HF trial) have explored SS-31's ability to restore mitochondrial function in cardiomyocytes, with encouraging early signals. Renal research has shown protection against cisplatin-induced nephrotoxicity and ischaemic kidney injury in animal models.
Ageing biology research has found SS-31 improving physical function and muscle metabolism in aged rodents, with some studies reporting improvements in exercise capacity and mitochondrial bioenergetics comparable to those seen in younger animals. These findings have made SS-31 a point of interest for longevity-focused researchers alongside compounds like NAD+ and MOTS-c that also target mitochondrial health. Optic Labs supplies SS-31 in 10mg format for research purposes.
Frequently Asked Questions
What makes SS-31 different from other antioxidant peptides?
SS-31 is specifically designed to accumulate in mitochondrial inner membranes where it interacts with cardiolipin, rather than acting as a general systemic antioxidant. This targeted localisation makes it more relevant to mitochondrial dysfunction specifically, distinguishing it from compounds like glutathione that act throughout the cell.
Has SS-31 been tested in humans?
Yes. SS-31 (Elamipretide) has entered clinical trials for heart failure and renal applications, making it one of the more clinically advanced research peptides. Results have been mixed across trials, with some showing functional improvements and others showing no significant primary endpoint benefit.
Is SS-31 legal in Australia?
SS-31 is not a scheduled substance in Australia and can be purchased for research purposes. It is not approved as a therapeutic agent in Australia.
How does SS-31 relate to MOTS-c in longevity research?
Both SS-31 and MOTS-c target mitochondrial function but through different mechanisms. SS-31 stabilises cardiolipin to improve electron transport chain efficiency and reduce ROS. MOTS-c is a mitochondria-derived peptide that regulates metabolic adaptation and glucose metabolism. Researchers studying mitochondrial health in ageing models may explore both compounds.
This article is for educational and research purposes only. Optic Labs products are intended for research use only and are not for human consumption. Always consult a qualified healthcare professional before considering any compounds.